Drug delivery nanosystems targeted to hepatic ischemia and reperfusion injury

[1]  W. Cai,et al.  Prevention of Hepatic Ischemia-Reperfusion Injury by Carbohydrate-Derived Nanoantioxidants. , 2020, Nano letters.

[2]  Kathleen M Spring,et al.  Delivering the power of nanomedicine to patients today , 2020, Journal of Controlled Release.

[3]  Shyh-Dar Li,et al.  Lipid-based nanoparticle technologies for liver targeting. , 2020, Advanced drug delivery reviews.

[4]  Minghua Deng,et al.  Macrophage Membrane-Coated Nanoparticles Alleviate Hepatic Ischemia-Reperfusion Injury Caused by Orthotopic Liver Transplantation by Neutralizing Endotoxin , 2020, International journal of nanomedicine.

[5]  Maie S. Taha,et al.  Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation , 2020, Drug Delivery and Translational Research.

[6]  T. Lammers,et al.  Challenges in nanomedicine clinical translation , 2020, Drug Delivery and Translational Research.

[7]  H. Santos,et al.  The solid progress of nanomedicine , 2020, Drug Delivery and Translational Research.

[8]  V. Mirakaj,et al.  Novel Resolution Mediators of Severe Systemic Inflammation , 2020, ImmunoTargets and therapy.

[9]  M. Manoharan,et al.  The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs , 2019, Nature Nanotechnology.

[10]  Samir Mitragotri,et al.  Nanoparticles in the clinic: An update , 2019, Bioengineering & translational medicine.

[11]  Zachary T. Rosenkrans,et al.  Ceria Nanoparticles Meet Hepatic Ischemia‐Reperfusion Injury: The Perfect Imperfection , 2019, Advanced materials.

[12]  P. Fagone,et al.  Effects of GIT-27NO, a NO-donating compound, on hepatic ischemia/reperfusion injury , 2019, International journal of immunopathology and pharmacology.

[13]  D. Ma,et al.  Hepatic ischemia-reperfusion injury in liver transplant setting: mechanisms and protective strategies. , 2019, Journal of biomedical research.

[14]  Stephen L. Jones,et al.  Cost-effectiveness of nanomedicine: estimating the real size of nano-costs. , 2019, Nanomedicine.

[15]  Heebeom Koo,et al.  Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems , 2019, Cancers.

[16]  Daniel G Anderson,et al.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  Michael R Hamblin,et al.  Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. , 2019, Nanomedicine.

[18]  C. Alexiou,et al.  From design to the clinic: practical guidelines for translating cardiovascular nanomedicine , 2018, Cardiovascular research.

[19]  F. Carrilho,et al.  Translational medical research and liver transplantation: systematic review. , 2018, Translational gastroenterology and hepatology.

[20]  F. Tacke,et al.  Machine perfusion for liver transplantation in the era of marginal organs—New kids on the block , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[21]  Guihua Chen,et al.  Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate rat hepatic ischemia‐reperfusion injury by suppressing oxidative stress and neutrophil inflammatory response , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Susan Hua,et al.  Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization , 2018, Front. Pharmacol..

[23]  K. Na-Bangchang,et al.  Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review , 2018, International journal of nanomedicine.

[24]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[25]  J. Pober,et al.  Focus on Fundamentals: Achieving Effective Nanoparticle Targeting. , 2018, Trends in molecular medicine.

[26]  E. Geissler,et al.  Targeting Innate Immune Cells and Regulated Cell Death in Early Hepatic Ischemia Reperfusion Injury , 2018, Transplantation.

[27]  Q. Xia,et al.  Dual Effect of Hepatic Macrophages on Liver Ischemia and Reperfusion Injury during Liver Transplantation , 2018, Immune network.

[28]  Kathleen A Cronin,et al.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics , 2018, Cancer.

[29]  G. Camussi,et al.  Extracellular Vesicles from Human Liver Stem Cells Reduce Injury in an Ex Vivo Normothermic Hypoxic Rat Liver Perfusion Model , 2018, Transplantation.

[30]  Jichun Yang,et al.  Novel Targets for Treating Ischemia-Reperfusion Injury in the Liver , 2018, International journal of molecular sciences.

[31]  C. H. Kim,et al.  Control of Innate and Adaptive Lymphocytes by the RAR-Retinoic Acid Axis , 2018, Immune network.

[32]  E. Furtado,et al.  Recent insights into mitochondrial targeting strategies in liver transplantation , 2018, International journal of medical sciences.

[33]  N. Halama,et al.  Neutralization of CD95 ligand protects the liver against ischemia-reperfusion injury and prevents acute liver failure , 2018, Zeitschrift für Gastroenterologie.

[34]  S. Howie,et al.  NKT cells are important mediators of hepatic ischemia-reperfusion injury , 2017, Transplant immunology.

[35]  C. Real,et al.  Therapeutic activity of superoxide dismutase‐containing enzymosomes on rat liver ischaemia‐reperfusion injury followed by magnetic resonance microscopy , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[36]  H. Maeda.  Polymer therapeutics and the EPR effect , 2017, Journal of drug targeting.

[37]  Dawei Li,et al.  Exosomes from Human-Induced Pluripotent Stem Cell–Derived Mesenchymal Stromal Cells (hiPSC-MSCs) Protect Liver against Hepatic Ischemia/ Reperfusion Injury via Activating Sphingosine Kinase and Sphingosine-1-Phosphate Signaling Pathway , 2017, Cellular Physiology and Biochemistry.

[38]  M. Durymanov,et al.  Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non‐cancerous applications , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[39]  S. Tas,et al.  Endothelial cells: From innocent bystanders to active participants in immune responses. , 2017, Autoimmunity reviews.

[40]  H. Tan,et al.  Use of everolimus in liver transplantation , 2017, World journal of hepatology.

[41]  Gautam K. Ginjupalli,et al.  Prophylactic Treatment with Cerium Oxide Nanoparticles Attenuate Hepatic Ischemia Reperfusion Injury in Sprague Dawley Rats , 2017, Cellular Physiology and Biochemistry.

[42]  Dong Yun Lee,et al.  Bilirubin nanoparticle preconditioning protects against hepatic ischemia-reperfusion injury. , 2017, Biomaterials.

[43]  Lu Wang,et al.  Down-regulation of nuclear HMGB1 reduces ischemia-induced HMGB1 translocation and release and protects against liver ischemia-reperfusion injury , 2017, Scientific Reports.

[44]  I. Toth,et al.  Recent advances in self‐assembled peptides: Implications for targeted drug delivery and vaccine engineering , 2017, Advanced drug delivery reviews.

[45]  V. Alves,et al.  Re-Transplantation, Higher Creatinine Levels in Hepatitis C Virus Patients, and Donor Age Are Predictors of Mortality in Long-Term Analysis of Late Acute Rejection in Liver Transplantation. , 2017, Annals of transplantation.

[46]  J. Lambert,et al.  Topically applied lipid- and surfactant-based nanoparticles in the treatment of skin disorders , 2017, Expert opinion on drug delivery.

[47]  L. Toledo-Pereyra,et al.  Akt: A Therapeutic Target in Hepatic Ischemia–Reperfusion Injury , 2017, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[48]  V. Préat,et al.  Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes , 2017, Expert opinion on drug delivery.

[49]  Issue Information ‐ Table of Contents , 2016, Glia.

[50]  Ian D. McGilvray,et al.  Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[51]  A. Oyelere,et al.  Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice? , 2016, Future medicinal chemistry.

[52]  R. Serra,et al.  Hepatic ischemia reperfusion injury: A systematic review of literature and the role of current drugs and biomarkers. , 2016, International journal of surgery.

[53]  Haoming Zhou,et al.  Innate Immune Regulations and Liver Ischemia-Reperfusion Injury. , 2016, Transplantation.

[54]  Wei-wei Wang,et al.  Carnosic acid nanoparticles suppress liver ischemia/reperfusion injury by inhibition of ROS, Caspases and NF-κB signaling pathway in mice. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[55]  G. Tisone,et al.  Use of Everolimus in Liver Transplantation: Recommendations From a Working Group , 2016, Transplantation.

[56]  S. Kawakami,et al.  Development of PEGylated Cysteine-Modified Lysine Dendrimers with Multiple Reduced Thiols To Prevent Hepatic Ischemia/Reperfusion Injury. , 2016, Molecular pharmaceutics.

[57]  K. Thurecht,et al.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.

[58]  I. Vassiliou,et al.  Beyond Preconditioning: Postconditioning as an Alternative Technique in the Prevention of Liver Ischemia-Reperfusion Injury , 2016, Oxidative medicine and cellular longevity.

[59]  K. Ulbrich,et al.  Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. , 2016, Chemical reviews.

[60]  Meng-yu Zhang,et al.  Overexpression of the long noncoding RNA TUG1 protects against cold‐induced injury of mouse livers by inhibiting apoptosis and inflammation , 2016, The FEBS journal.

[61]  Dongwon Lee,et al.  H2O2-triggered bubble generating antioxidant polymeric nanoparticles as ischemia/reperfusion targeted nanotheranostics. , 2016, Biomaterials.

[62]  William R Wilson,et al.  Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review. , 2016, Biomaterials.

[63]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[64]  J. Roselló-Catafau,et al.  Polyethylene Glycol Preconditioning: An Effective Strategy to Prevent Liver Ischemia Reperfusion Injury , 2016, Oxidative medicine and cellular longevity.

[65]  A. Maity,et al.  Limited Efficiency of Drug Delivery to Specific Intracellular Organelles Using Subcellularly "Targeted" Drug Delivery Systems. , 2016, Molecular pharmaceutics.

[66]  Vanessa Sainz,et al.  Regulatory aspects on nanomedicines. , 2015, Biochemical and biophysical research communications.

[67]  David V Schaffer,et al.  Viral Vectors for Gene Therapy: Translational and Clinical Outlook. , 2015, Annual review of biomedical engineering.

[68]  Mauro Ferrari,et al.  Safety of Nanoparticles in Medicine. , 2015, Current drug targets.

[69]  Pedro Pedrosa,et al.  Gold Nanotheranostics: Proof-of-Concept or Clinical Tool? , 2015, Nanomaterials.

[70]  J. Rao,et al.  Hyperglycemia and Liver Ischemia Reperfusion Injury: A Role for the Advanced Glycation Endproduct and Its Receptor Pathway , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[71]  D. Granger,et al.  Reperfusion injury and reactive oxygen species: The evolution of a concept☆ , 2015, Redox biology.

[72]  P. Quesenberry,et al.  Role of extracellular RNA-carrying vesicles in cell differentiation and reprogramming , 2015, Stem Cell Research & Therapy.

[73]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[74]  T. Billiar,et al.  Damage‐associated molecular pattern–activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury , 2015, Hepatology.

[75]  C. Peralta,et al.  Molecular pathways in protecting the liver from ischaemia/reperfusion injury: a 2015 update. , 2015, Clinical science.

[76]  M. Schilsky,et al.  Review on immunosuppression in liver transplantation. , 2015, World journal of hepatology.

[77]  V. Torchilin,et al.  New Developments in Liposomal Drug Delivery. , 2015, Chemical reviews.

[78]  M. Amiji,et al.  Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases , 2015, The AAPS Journal.

[79]  E. Hatano,et al.  A Systematic Review of Pharmacological Treatment Options Used to Reduce Ischemia Reperfusion Injury in Rat Liver Transplantation , 2015, PloS one.

[80]  M. Roberts,et al.  Diagnostic imaging and therapeutic application of nanoparticles targeting the liver. , 2015, Journal of materials chemistry. B.

[81]  Pedro M. Baptista,et al.  Emerging concepts in liver graft preservation. , 2015, World journal of gastroenterology.

[82]  J. Roselló-Catafau,et al.  Polyethylene glycol rinse solution: an effective way to prevent ischemia-reperfusion injury. , 2014, World journal of gastroenterology.

[83]  R. Saidi,et al.  Liver Ischemia/Reperfusion Injury: an Overview , 2014, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[84]  J. Zweier,et al.  Measurement and Characterization of Superoxide Generation from Xanthine Dehydrogenase: A Redox-Regulated Pathway of Radical Generation in Ischemic Tissues , 2014, Biochemistry.

[85]  K. Kalimeris,et al.  Global Consequences of Liver Ischemia/Reperfusion Injury , 2014, Oxidative medicine and cellular longevity.

[86]  S. Svenson,et al.  What nanomedicine in the clinic right now really forms nanoparticles? , 2014, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[87]  G. Klintmalm,et al.  The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence , 2014, Journal of transplantation.

[88]  J. Lovrić,et al.  Nanotherapeutics in the EU: an overview on current state and future directions , 2014, International journal of nanomedicine.

[89]  C. Peralta,et al.  Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu. , 2013, Journal of hepatology.

[90]  A. Kukla,et al.  Calcineurin Inhibitor Nephrotoxicity: A Review and Perspective of the Evidence , 2013, American Journal of Nephrology.

[91]  P. Doevendans,et al.  Targeting cell death in the reperfused heart: pharmacological approaches for cardioprotection. , 2013, International journal of cardiology.

[92]  Johnny C. Hong,et al.  Ischaemia–reperfusion injury in liver transplantation—from bench to bedside , 2013, Nature Reviews Gastroenterology &Hepatology.

[93]  G. Wagener.  Liver Anesthesiology and Critical Care Medicine , 2012, Springer International Publishing.

[94]  J. Parfitt,et al.  Reduction of liver ischemia reperfusion injury by silencing of TNF-α gene with shRNA. , 2012, The Journal of surgical research.

[95]  R. Schiffelers,et al.  Drug targeting systems for inflammatory disease: one for all, all for one. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[96]  S. Kawakami,et al.  Efficient suppression of murine intracellular adhesion molecule‐1 using ultrasound‐responsive and mannose‐modified lipoplexes inhibits acute hepatic inflammation , 2012, Hepatology.

[97]  Judit Tulla-Puche,et al.  Polymers and drug delivery systems. , 2012, Current drug delivery.

[98]  Tao Wang,et al.  Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. , 2012, International journal of pharmaceutics.

[99]  V. Torchilin,et al.  Challenges in Development of Targeted Liposomal Therapeutics , 2012, The AAPS Journal.

[100]  H. Metselaar,et al.  Optimization of the use of Calcineurin inhibitors in liver transplantation. , 2012, Best practice & research. Clinical gastroenterology.

[101]  S M Moghimi,et al.  Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. , 2012, Annual review of pharmacology and toxicology.

[102]  T. Eckle,et al.  Ischemia and reperfusion—from mechanism to translation , 2011, Nature Medicine.

[103]  R. Duncan,et al.  Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.

[104]  G. Tsokos,et al.  Immunopathogenesis of ischemia/reperfusion-associated tissue damage. , 2011, Clinical immunology.

[105]  D. Schuppan,et al.  Targeted therapy of liver fibrosis/cirrhosis and its complications. , 2011, Journal of hepatology.

[106]  T. Ichim,et al.  Targeted Gene Silencing of TLR4 Using Liposomal Nanoparticles for Preventing Liver Ischemia Reperfusion Injury , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[107]  R. Duncan.  Polymer therapeutics as nanomedicines: new perspectives. , 2011, Current opinion in biotechnology.

[108]  Bo Yu,et al.  Receptor-targeted nanocarriers for therapeutic delivery to cancer , 2010, Molecular membrane biology.

[109]  William B. Liechty,et al.  Polymers for drug delivery systems. , 2010, Annual review of chemical and biomolecular engineering.

[110]  Z. Si,et al.  Recombinant adenovirus vector Ad-hIL-10 protects grafts from cold ischemia-reperfusion injury following orthotopic liver transplantation in rats. , 2010, Hepatobiliary & pancreatic diseases international : HBPD INT.

[111]  Xuetao Cao,et al.  Interleukin-17 and its expanding biological functions , 2010, Cellular and Molecular Immunology.

[112]  N. Mahmud,et al.  Antibody immunosuppressive therapy in solid-organ transplant , 2010 .

[113]  A. Lamprecht,et al.  Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases , 2010, Journal of The Royal Society Interface.

[114]  G. Plitas,et al.  Toll‐like receptor 9 inhibition confers protection from liver ischemia–reperfusion injury , 2010, Hepatology.

[115]  Z. Si,et al.  Cytoprotective effects of human interleukin-10 gene transfer against necrosis and apoptosis induced by hepatic cold ischemia/reperfusion injury. , 2009, The Journal of surgical research.

[116]  J. Levitsky,et al.  Overview of immunosuppression in liver transplantation. , 2009, World journal of gastroenterology.

[117]  G. Camussi,et al.  Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats , 2009, Journal of cellular and molecular medicine.

[118]  Yoon Yeo,et al.  Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. , 2009, Molecular pharmaceutics.

[119]  S. Zahler,et al.  Reciprocal Activation Between CD4+ T Cells and Kupffer Cells During Hepatic Ischemia-Reperfusion , 2008, Transplantation.

[120]  Scott M. Grayson,et al.  The role of macromolecular architecture in passively targeted polymeric carriers for drug and gene delivery , 2008 .

[121]  Daniel S Kohane,et al.  Microparticles and nanoparticles for drug delivery. , 2007, Biotechnology and bioengineering.

[122]  Guihua Chen,et al.  Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction of small interference RNA targeting Fas , 2007, Langenbeck's Archives of Surgery.

[123]  R. Malthaner,et al.  Cyclosporin versus tacrolimus for liver transplanted patients. , 2006, The Cochrane database of systematic reviews.

[124]  P. Couvreur,et al.  Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.

[125]  A. Moshfeghi,et al.  Micro- and nanoparticulates. , 2005, Advanced drug delivery reviews.

[126]  N. Selzner,et al.  Principles of Liver Preservation , 2005 .

[127]  H. Dietz,et al.  A novel chimeric ribozyme vector produces potent inhibition of ICAM‐1 expression on ischemic vascular endothelium , 2004, Journal of Gene Medicine.

[128]  Won Ho Kim,et al.  IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[129]  S. Fan,et al.  Interleukin‐2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosage , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[130]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[131]  G. Farrell,et al.  Hepatic ischemia reperfusion injury: Pathogenic mechanisms and basis for hepatoprotection , 2003, Journal of gastroenterology and hepatology.

[132]  R. Guyton,et al.  Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. , 2003, American journal of physiology. Heart and circulatory physiology.

[133]  M. Wauben,et al.  Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. , 2003, Arthritis and rheumatism.

[134]  M. Kitajima,et al.  Transfer Of The Interleukin-1 Receptor Antagonist Gene Into Rat Liver Abrogates Hepatic Ischemia-Reperfusion Injury , 2002, Transplantation.

[135]  K. Ley,et al.  Blocking P‐selectin protects from ischemia/reperfusion‐induced acute renal failure , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[136]  J. Contreras,et al.  Reduction of ischemia-reperfusion injury of the liver by in vivo adenovirus-mediated gene transfer of the antiapoptotic Bcl-2 gene. , 1999, Annals of surgery.

[137]  C. Smith,et al.  Intercellular adhesion molecule 1 (ICAM‐1) expression and its role in neutrophil‐induced ischemia‐reperfusion injury in rat liver , 1995, Journal of leukocyte biology.

[138]  H. Jaeschke,et al.  Mitochondria and xanthine oxidase both generate reactive oxygen species in isolated perfused rat liver after hypoxic injury. , 1989, Biochemical and biophysical research communications.

[139]  J H Southard,et al.  Principles of solid-organ preservation by cold storage. , 1988, Transplantation.

[140]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[141]  R. Jennings,et al.  Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. , 1986, Circulation.

[142]  E. Chain,et al.  Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: a study of myocardial enzyme release. , 1973, Journal of molecular and cellular cardiology.

[143]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[144]  N. Lukacs,et al.  Acute and chronic inflammation induces disease pathogenesis , 2020, Essential Concepts in Molecular Pathology.

[145]  Marco Hoffmann,et al.  Changing the Way of Entrance: Highly Efficient Transfer of mRNA and siRNA via Fusogenic Nano-Carriers. , 2019, Journal of biomedical nanotechnology.

[146]  J. Pontes,et al.  Evaluation of the Effects of Atorvastatin and Ischemic Postconditioning Preventing on the Ischemia and Reperfusion Injury: Experimental Study in Rats , 2018, Brazilian journal of cardiovascular surgery.

[147]  C. Sharma,et al.  Drug delivery nanosystems—An introduction , 2018 .

[148]  A. Sosnik.  From the “Magic Bullet” to Advanced Nanomaterials for Active Targeting in Diagnostics and Therapeutics , 2018 .

[149]  R. Schuster,et al.  Hepatocyte exosomes mediate liver repair and regeneration via sphingosine-1-phosphate. , 2016, Journal of hepatology.

[150]  H. Petrowsky,et al.  Chapter 44 – Principles of Liver Preservation , 2015 .

[151]  H. S. Marinho,et al.  Superoxide Dismutase Enzymosomes: Carrier Capacity Optimization, in Vivo Behaviour and Therapeutic Activity , 2014, Pharmaceutical Research.

[152]  Mafalda Videira,et al.  Regulatory Aspects of Oncologicals: Nanosystems Main Challenges , 2014 .

[153]  Wayne M. Mullett,et al.  Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials , 2013 .

[154]  J. Klinck.  History of Liver Transplantation , 2012 .

[155]  N. Mahmud,et al.  Antibody immunosuppressive therapy in solid-organ transplant: Part I. , 2010, mAbs.

[156]  Mozow,et al.  Ischemia/Reperfusion. , 2016, Comprehensive Physiology.

[157]  W. Godbey,et al.  The role of macromolecular architecture in passively targeted polymeric carriers for drug and gene delivery. , 2008, Journal of drug targeting.

[158]  V. Torchilin,et al.  Drug targeting. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[159]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[160]  F. Henry,et al.  Cost effectiveness. , 1980, The Ohio State medical journal.